You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Advanced melanoma

Showing 1 - 25 of >10,000
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Melanoma Trial in Beijing (IBI363)

Not yet recruiting
  • Melanoma
  • IBI363
  • Beijing, Beijing, China
    Beijing Cancer Hospital
Oct 7, 2023

Advanced Melanoma Trial in Basel (Combination of Tumor-infiltrating lymphocyte transfer with ANV419)

Not yet recruiting
  • Advanced Melanoma
  • Combination of Tumor-infiltrating lymphocyte transfer with ANV419
  • Basel, Switzerland
    University Hospital Basel
May 19, 2023

Melanoma Trial (Fluzoparib Camrelizumab Temozolomide)

Not yet recruiting
  • Melanoma
  • Fluzoparib Camrelizumab Temozolomide
  • (no location specified)
Aug 9, 2023

Melanoma, Malignant Melanoma Trial (T3011 + Cobimetinib)

Not yet recruiting
  • Melanoma
  • Malignant Melanoma
  • T3011 + Cobimetinib
  • (no location specified)
Mar 3, 2023

Gut and Tumor Microbiome in Advanced ER-positive and

Not yet recruiting
  • Breast Cancer
  • Melanoma
  • Observation
  • (no location specified)
Nov 6, 2023

Advanced Melanoma, Tumor Infiltrating Lymphocyte, Treatment Side Effects Trial in Shanghai (Tumor Infiltrating Lymphocyte)

Recruiting
  • Advanced Melanoma
  • +3 more
  • Tumor Infiltrating Lymphocyte
  • Shanghai, China
    Shanghai Tenth People's Hospital
Dec 19, 2022

Melanoma Trial in Philadelphia (Mature dendritic cell (DC) vaccine, Cyclophosphamide 300mg/m^2, Pembrolizumab)

Active, not recruiting
  • Melanoma
  • Mature dendritic cell (DC) vaccine
  • +2 more
  • Philadelphia, Pennsylvania
    University of Pennsylvania
Feb 2, 2023

Advanced Melanoma Trial in New Brunswick (Propranolol, Naltrexone)

Not yet recruiting
  • Advanced Melanoma
  • New Brunswick, New Jersey
    Rutgers Cancer Institute of New Jersey
Jul 18, 2023

Tumor Infiltrating Lymphocytes, Safety, Melanoma Trial in Beijing (GC101 TIL)

Recruiting
  • Tumor Infiltrating Lymphocytes
  • +4 more
  • GC101 TIL
  • Beijing, China
    Beijing Cancer Hospital
Nov 7, 2023

Melanoma Trial in Beijing (KD6001, Toripalimab)

Not yet recruiting
  • Melanoma
  • Beijing, China
    Beijing Cancer Hospital
Feb 3, 2023

Advanced Melanoma Trial (Tebentafusp, Tebentafusp with Pembrolizumab, Investigators Choice)

Not yet recruiting
  • Advanced Melanoma
  • (no location specified)
Sep 19, 2022

Melanoma Trial in Toulouse (Nivolumab+Ipilimumab in combination with Anti TNF-a Certolizumab, Nivolumab+Ipilimumab in

Active, not recruiting
  • Melanoma
  • Nivolumab+Ipilimumab in combination with Anti TNF-α Certolizumab
  • Nivolumab+Ipilimumab in combination with Anti TNF-α Infliximab
  • Toulouse, France
    Institut Claudius Regaud IUCT-ONCOPOLE
Nov 18, 2022

Advanced Melanoma Trial in Zhengzhou (Tislelizumab Injection)

Not yet recruiting
  • Advanced Melanoma
  • Tislelizumab Injection
  • Zhengzhou, Henan, China
    Department of Bone and Soft Tissue ,Henan Cancer Hospital
Aug 4, 2022

Advanced Melanoma

Enrolling by invitation
  • Melanoma
  • observational
  • Durham, North Carolina
    Duke University Medical Center
Aug 16, 2022

Melanoma Trial in Aurora (VESANOID, Ipilimumab)

Active, not recruiting
Has Results
  • Melanoma
  • Aurora, Colorado
    University of Colorado Hospital
Sep 7, 2022

Melanoma, Urothelial Carcinoma Trial in China (QLF31907)

Not yet recruiting
  • Melanoma
  • Urothelial Carcinoma
  • Beijing, Beijing, China
  • +5 more
Apr 9, 2023

the Efficacy and Safety of PD-1 Inhibitors With or Without Radiotherapy in Patients With Advanced Melanoma Trial in Shanghai

Not yet recruiting
  • the Efficacy and Safety of PD-1 Inhibitors With or Without Radiotherapy in Patients With Advanced Melanoma
  • Radiation
  • Shanghai, Shanghai, China
    Fudan University Shanghai Cencer Center
Aug 10, 2022

Cutaneous Melanoma, NSCLC, Colorectal Tumors Trial in Denver (SGN-BB228)

Recruiting
  • Cutaneous Melanoma
  • +4 more
  • Denver, Colorado
    Sarah Cannon Research Institute at HealthONE - Denver
Jan 17, 2023

Melanoma Trial in Tampa (Ipilimumab, Axitinib)

Recruiting
  • Melanoma
  • Tampa, Florida
    Moffitt Cancer Center
Jun 21, 2022

PD-1 Refractory Advanced Melanoma Trial in Pittsburgh (Responder-Derived Fecal microbiota transplantation (R-FMT, Pembrolizumab,

Not yet recruiting
  • PD-1 Refractory Advanced Melanoma
  • Responder-Derived Fecal microbiota transplantation (R-FMT
  • +2 more
  • Pittsburgh, Pennsylvania
    UPMC Hillman Cancer Center
Sep 1, 2023

Advanced Melanoma Trial in New York, Houston (LTX-315 in combination with pembrolizumab)

Recruiting
  • Advanced Melanoma
  • LTX-315 in combination with pembrolizumab
  • New York, New York
  • +7 more
Jan 23, 2023

Melanoma Trial in Tampa (CC-122, Nivolumab)

Completed
Has Results
  • Melanoma
  • Tampa, Florida
    H Lee Moffitt Cancer Center and Research Institute
Sep 27, 2022

Melanoma Trial (Chidamide combined with Toripalimab)

Not yet recruiting
  • Melanoma
  • Chidamide combined with Toripalimab
  • (no location specified)
Jul 27, 2022

Melanoma Trial in Aurora (PI-88)

Completed
  • Melanoma
  • Aurora, Colorado
    University of Colorado Health Sciences Center
Jun 21, 2022

Advanced Melanoma, Metastatic Melanoma Trial in Saint Louis (Memory-like natural killer cells, Relatilmab, Nivolumab)

Not yet recruiting
  • Advanced Melanoma
  • Metastatic Melanoma
  • Memory-like natural killer cells
  • +2 more
  • Saint Louis, Missouri
    Washington University School of Medicine
Nov 16, 2022